250 related articles for article (PubMed ID: 35293692)
41. PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lau SCM; Rabindranath M; Weiss J; Li JJN; Fung AS; Mullen D; Alshamlan N; Ruff HM; Tong LCB; Pal P; Cabanero MR; Hsu YR; Sacher AG; Shepherd FA; Liu G; Bradbury PA; Yasufuku K; Czarnecka-Kujawa K; Mi Ko H; Tsao MS; Leighl NB; Schwock J
Lung Cancer; 2022 Sep; 171():42-46. PubMed ID: 35907387
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
[TBL] [Abstract][Full Text] [Related]
43. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
[TBL] [Abstract][Full Text] [Related]
44. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
Ilie M; Long-Mira E; Bence C; Butori C; Lassalle S; Bouhlel L; Fazzalari L; Zahaf K; Lalvée S; Washetine K; Mouroux J; Vénissac N; Poudenx M; Otto J; Sabourin JC; Marquette CH; Hofman V; Hofman P
Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy and lung cytopathology: Overview and possibilities.
Lozano MD; Argueta A; de Andrea C
Cytopathology; 2024 Mar; 35(2):213-217. PubMed ID: 37968806
[TBL] [Abstract][Full Text] [Related]
46. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
Smith A; Wang H; Zerbo A; Beaudoin S; Ofiara L; Fiset PO; Benedetti A; Gonzalez AV
J Bronchology Interv Pulmonol; 2020 Jan; 27(1):50-57. PubMed ID: 31513030
[TBL] [Abstract][Full Text] [Related]
47. Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.
Abdo M; Belloum Y; Heigener D; Welker L; von Weihe S; Schmidt M; Heuer-Olewinski N; Watermann I; Szewczyk M; Kropidlowski J; Pereira-Veiga T; Elmas H; Perner S; Steurer S; Wikman H; Pantel K; Reck M
Mol Oncol; 2023 May; 17(5):737-746. PubMed ID: 36892210
[TBL] [Abstract][Full Text] [Related]
48. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
[TBL] [Abstract][Full Text] [Related]
49. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
Grosu HB; Arriola A; Stewart J; Ma J; Bassett R; Hernandez M; Ost D; Roy-Chowdhuri S
Respirology; 2019 Dec; 24(12):1198-1203. PubMed ID: 31209954
[TBL] [Abstract][Full Text] [Related]
50. Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma.
Hernandez A; Brandler TC; Chen F; Zhou F; Xia Y; Zhong J; Moreira AL; Simms A; Sun W; Wei XJ; Simsir A
Am J Clin Pathol; 2020 Sep; 154(4):517-524. PubMed ID: 32589185
[TBL] [Abstract][Full Text] [Related]
51. PD-L1 and beyond: Immuno-oncology in cytopathology.
Iaccarino A; Salatiello M; Migliatico I; De Luca C; Gragnano G; Russo M; Bellevicine C; Malapelle U; Troncone G; Vigliar E
Cytopathology; 2021 Sep; 32(5):596-603. PubMed ID: 33955097
[TBL] [Abstract][Full Text] [Related]
52. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
[TBL] [Abstract][Full Text] [Related]
53. Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.
Munari E; Zamboni G; Sighele G; Marconi M; Sommaggio M; Lunardi G; Rossi G; Cavazza A; Moretta F; Gilioli E; Caliò A; Netto GJ; Hoque MO; Martignoni G; Brunelli M; Vacca P; Moretta L; Bogina G
Cancer Cytopathol; 2019 Feb; 127(1):52-61. PubMed ID: 30500997
[TBL] [Abstract][Full Text] [Related]
54. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840
[TBL] [Abstract][Full Text] [Related]
55. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
Ratcliffe MJ; Sharpe A; Midha A; Barker C; Scott M; Scorer P; Al-Masri H; Rebelatto MC; Walker J
Clin Cancer Res; 2017 Jul; 23(14):3585-3591. PubMed ID: 28073845
[No Abstract] [Full Text] [Related]
56. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
Nambirajan A; Husain N; Shukla S; Kumar S; Jain D
Indian J Med Res; 2019 Oct; 150(4):376-384. PubMed ID: 31823919
[TBL] [Abstract][Full Text] [Related]
57. Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
Schats KA; Van Vré EA; Boeckx C; De Bie M; Schrijvers DM; Neyns B; De Meester I; Kockx MM
Arch Pathol Lab Med; 2018 Aug; 142(8):982-991. PubMed ID: 29607663
[TBL] [Abstract][Full Text] [Related]
58. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
[TBL] [Abstract][Full Text] [Related]
59. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
[TBL] [Abstract][Full Text] [Related]
60. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
Perrotta F; Nankivell M; Adizie JB; Maqsood U; Elshafi M; Jafri S; Lerner AD; Woolhouse I; Munavvar M; Evison M; Booton R; Baldwin DR; Janes SM; Kerr KM; Bianco A; Yarmus L; Navani N
Chest; 2020 Sep; 158(3):1230-1239. PubMed ID: 32428509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
